Price
$54.90
Decreased by -2.54%
Dollar volume (20D)
17.10 M
ADR%
4.62
Shares float
29.05 M
Shares short
6.87 M [23.63%]
Shares outstanding
43.19 M
Market cap
3.19 B
Beta
N/A
Price/earnings
N/A
20D range
50.93 58.00
50D range
46.09 60.82
200D range
30.98 72.29

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.

The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD.

Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Feb 28, 24 0.00 -0.50
Increased by +100.00%
Nov 13, 23 -0.51 -0.41
Decreased by -24.39%
Jul 17, 23 -3.78 -1.70
Decreased by -122.35%
May 31, 23 -2.38 -
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 0.00
Decreased by N/A%
-20.84 M
Decreased by N/A%
Decreased by N/A%
-
Jun 30, 23 0.00
Decreased by N/A%
-18.89 M
Decreased by N/A%
Decreased by N/A%
-
Mar 31, 23 0.00 - -12.53 M -
Decreased by N/A%
-
Sep 30, 22 N/A - -19.66 M - - -
Jun 30, 22 N/A - N/A - - -
Mar 31, 22 N/A - N/A - - -
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY